The Top 100 Cited Research Bioactive Small Molecules: 2026 Analysis
5
Min Read
In this blog:
- MilliporeSigma, MedChemExpress and Selleck Chemicals saw with the most cited Bioactive Small Molecules of the past year
- Cancer-associated small molecules - many of them clinically approved cancer drugs - and protein kinase inhibitors claimed high citation counts
- Download data on the top 100 Bioactive Small Molecules for your own analysis and see if you rank!
CiteAb collects information on product use in the scientific literature, curating an industry-leading life science reagent database that powers data services for suppliers & pharma companies, and a search platform to help scientists find the right products, faster.
Welcome to the Top 100 series for 2026!
In this blog, we’re digging into the Top 100 most-cited Bioactive Small Molecules in life science research over the past year – surfacing the products and vendors supporting a huge share of the field’s experimental work.
Data & Methodology
Through the development of patent-protected text mining technology, we have amassed information on tens of thousands of bioactive small molecules. Our biochemicals database in its entirety covers nearly 3 million products from over 300 suppliers.
We specifically focus on citation counts: a measure of how frequently a product appears in peer-reviewed, published research. This data helps researchers see what their peers are reaching for, and gives suppliers a leading indicator of future demand as well as insight into past research activity.
This Top 100 analysis draws from the previous year’s worth of data, across all suppliers, ranking bioactive small molecule products by citation count.
The Bioactive Small Molecule Suppliers Supporting a Significant Volume of Research
Growing competition at the top of the bioactive market
Leading the Top 100 rankings were MilliporeSigma. Their products claimed 40% of spots, demonstrating their support of a large volume of research.
We’d previously flagged MedChemExpress as a company to watch. They’ve certainly seen growth in the bioactive space, doubling their presence in the Top 100 to claim 22 products in the dataset.
Selleck Chemicals held the third most products in the rankings.
Beyond these 3 vendors, the rankings saw dedicated bioactive-compound specialists sitting alongside larger life science reagent companies.
We noted growth in the number of suppliers making the Top 100: 15 compared to the 13 that featured when we analysed our data last year.
China-founded or China-based companies also saw a growing prescence, a signal that this region continues to succeed in the global reagent market.
The Top Cited Research Bioactive Small Molecules Leading the Market
Cancer-associated compounds, epigenetic modifiers and cocktail inhibitors are strongly represented in the Top 100
Firstly, the prevalence of protease inhibitor cocktails in the Top 100 jumped out. With 14 featuring, these fundamental lab tools continue to support a significant amount of research alongside more specialist compounds.
Expanding out, we saw epigenetics, ferroptosis, and stem cell research tools all carved out solid representation too.
Epigenetic inhibitors included 5-Azacytidine, 5-Aza-2′-deoxycytidine (DNMT inhibitors), and Vorinostat (SAHA) (an HDAC inhibitor) all sitting in the top 30, plus others.
Looking at ferroptosis and stem cell research tools, we found that clusters of supporting products ranked. This suggests labs are buying complete toolkits rather than single compounds. Examples included:
- Y-27632 (ROCK inhibitor), CHIR99021 (GSK3/Wnt activator), and A 83-01 (TGF-β inhibitor), tools used in stem cell research.
- The Ferrostatin-1 (inhibitor) paired with Erastin (inducer) used to study ferroptosis – iron-driven cell death.
Bioactive Compounds to Watch
Cancer drugs seeing a second lease of life
Topping the Top 100 this year was Regorafenib, supplied by Selleck Chemicals. This is a repurposed targeted cancer therapy that appeared in the Top 10 three separate times from different suppliers.
This points to a broader theme running through the data: the continued rise of multi-kinase inhibitors that started as cancer treatments and have found a second wind as research tools.
In Regorafenib’s case, the drug is primarily used to treat primary liver cancer, gastrointestinal stromal tumours and bowel cancer. [1]
Other widely cited inhibitors in the Top 100 included Dasatinib and Sunitinib.
Researchers may be using these reagents, sold as research-grade small molecule inhibitors, for the study of resistance mechanisms, signalling research in cell/animal models, target validation and more.
Looking for product trends beyond the top 100? Reach out to the team here about our market data services.
Wrap-up and Data Download
Dr Andrew Chalmers, CEO of CiteAb, commented on the analysis:
“The Top 100 Bioactive list gives insight into the tools and suppliers supporting a significant amount of research. With the continued rise of players like MedChemExpress in this dataset, it goes to show just how much movement there still is in this market, and how suppliers are evolving to support researchers with highly cited tools.’
Don’t hesitate to freely download the full list of the Top 100 Bioactive Compounds below. Gain actionable insights to better inform your product decisions, and see if you feature!
Finally, explore more Top 100 Reports via the links below:
- Top 100 Research Protein Report
- Top 100 Life Science Instruments Report
- Top 100 Life Science Kits & Assays Report
- Top 100 Cell Lines Report
- Top 100 Research Antibody Report
Sign up for data
Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.
References
[1]https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/regorafenib
FAQs
We build the Top 100 list by analysing our database of life science publications for citations of bioactive small molecules. Products are ranked by their share of citations across the past year.
This analysis is published annually. You can find last year’s edition, the 2025 Top 100 Cited Bioactive Small Molecules Analysis, here.
Sales figures remain locked inside each individual company’s own records, while citation data covers the entire market. Scientists commonly use citation data to inform future purchasing, which is why citation trends give an outlook on where the market is going.
Citation data shows exactly how researchers are putting bioactive small molecules to use. This equips product teams with actionable insight when building pipelines or refining catalogues, supports benchmarking across the full market, and enables trend-driven sales and marketing campaigns.
